Heron Q2 FY26 net loss widens to $5.49 million; net sales rise 1.3% to $37.67 million

Reuters2026/08/10 12:09

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Heron Therapeutics posted Q2 2026 net sales of $37.7 million, up 9% from Q1 2026.
Net loss widened to $5.49 million; GAAP basic EPS was $(0.03).
Acute Care net sales rose 43.9% year-over-year to $15.33 million, led by APONVIE up 73.6% to $4.28 million.
Oncology net sales fell 15.9% year-over-year to $22.33 million, with CINVANTI down 9.7% to $21.79 million.
Withdrew full-year 2026 guidance, citing uncertainty on generic entry timing for CINVANTI, paused salesforce expansion, strategic alternatives review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heron Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608100800PRIMZONEFULLFEED9806502) on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Heron Q2 FY26 net loss widens to $5.49 million; net sales rise 1.3% to $37.67 million

You may also like

Crypto prices